Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

8.770 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Aurinia Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
What's Going On With Aurinia Pharmaceuticals Stock Today?
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig 
Via Benzinga
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Preview: Aurinia Pharmaceuticals's Earnings
Via Benzinga
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Shares of Aurinia Pharmaceuticals Soared This Week
A patent settlement and improved financials sent the stock soaring. 
Via The Motley Fool
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
These 2 Healthcare Stocks Have Doubled in 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks. 
Via MarketBeat
Aurinia Announces PTAB Has Terminated Inter Partes Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Via Benzinga
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments. 
Via Benzinga
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Is Aurinia Pharmaceuticals (AUPH) Stock Down 30%?
Despite strong Q3 earnings, shares of AUPH stock are in steep decline today after it lowered its full-year sales guidance. 
Via InvestorPlace
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the latest news behind the biggest pre-market stock movers for Thursday morning! 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
Recap: Aurinia Pharmaceuticals Q3 Earnings
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
Via Benzinga
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
Earnings Preview For Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback